Belvedere Trading
RNAC icon

Belvedere Trading’s Cartesian Therapeutics RNAC Stock Holding History

Belvedere Trading’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-690
Closed -$23.4K – 1357
2022
Q4 		$23.4K Sell
690
-786
-53% -$33.4K ﹤0.01% 802
2022
Q3 		$75K Buy
+1,476
New +$81.1K ﹤0.01% 208

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Belvedere Trading's RNAC Position: Q1 2023 in Review

Belvedere Trading sold out of Cartesian Therapeutics (RNAC) in Q1 2023, closing a stake of 690 shares — an estimated $23.4K sold.

Belvedere Trading first reported a position in RNAC in Q3 2022 and held it in 2 quarters. The position peaked at $75K in Q3 2022. 93 funds tracked by Wall St. Rank hold RNAC as of Q1 2023.

  • Belvedere Trading reported no remaining Cartesian Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Belvedere Trading sold 690 Cartesian Therapeutics shares in Q1 2023, an estimated $23.4K.
  • Belvedere Trading first reported a position in Cartesian Therapeutics in Q3 2022 and held it in 2 quarters.
  • Belvedere Trading's Cartesian Therapeutics position peaked at $75K in Q3 2022.
  • 93 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.